US Mosquito Statistics 2026: State-by-State Data, Mosquito Season, Disease Trends & Bite Rates

---

1. Executive Summary

This US Mosquito Report consolidates the most current publicly available U.S. mosquito data through early 2026, drawing on surveillance records from the CDC ArboNET system, CDC Morbidity and Mortality Weekly Reports (MMWR), CDC Health Alert Network (HAN) advisories, EPA vector-control resources, and market intelligence from the mosquito control industry. Where 2026 data are unavailable or incomplete, data from the 2024 and 2025 seasons are cited with source dates noted. All forward-looking estimates are labeled Projected 2026 Estimate.

Key Confirmed Findings:

• 176 recognized mosquito species exist in the United States [1], spanning all 50 states and U.S. territories.
• West Nile virus (WNV) remains the leading mosquito-borne disease in the contiguous U.S. The CDC MMWR (2025) states WNV causes an average of approximately 2,000 disease cases annually, including approximately 1,200 neuroinvasive cases and 120 deaths [2]. In 2024 (preliminary, as of Jan 16, 2026), 1,791 human WNV cases were reported to ArboNET, including 161 fatalities [3].
• In 2025, WNV activity increased substantially. AMA infectious-diseases director Dr. Erica Kaufman West stated at an AMA-CDC joint webinar (December 5, 2025): ‘In 2025, there’s been a substantial increase in West Nile virus activity with 41% more severe-disease cases and 32% more deaths than what is typically seen with West Nile disease’ [4]. Over 2,000 WNV cases were reported as of December 17, 2025 [5].
• Dengue fever reached record levels in the Americas in 2024 (13 million cases regionally). In Puerto Rico, 6,291 dengue cases were confirmed, with 52.3% hospitalized and 11-13 fatalities reported (11 per MMWR [6]; 13 per CDC HAN-00523 [7] as a later operational count).
• EEE in 2024: 19 human cases reported across 9 states (MA 4, NH 5, NY 2, NJ 2, VT 2, RI 1, WI 1, ME 1, NC 1). Thirteen of 19 cases occurred in New England states [3]. The national annual average is 11 cases [8].
• More than two-thirds of the contiguous U.S. experienced an increase in ‘mosquito days’ over the past four decades, with the Northeast seeing the largest increases; some cities gained 13-17 additional mosquito-suitable days compared to the 1980-2009 baseline [9].
• The U.S. mosquito control market was valued at approximately $1.87 billion in 2024, with a projected compound annual growth rate of 6.5% through 2031 [10].
• Published climate modeling projects that by 2050, warming autumns and earlier springs could extend the U.S. mosquito season by up to two months in affected regions [11].
• Projected 2026 Estimate: Continued range expansion of Aedes aegypti and Aedes albopictus into previously unaffected northern states is expected, elevating localized dengue transmission risk in new geographies.

Note on case counts: Reported cases represent confirmed, notifiable-disease reports submitted to ArboNET. Because the majority of WNV infections are asymptomatic (approximately 80%) and mild non-neuroinvasive illness is significantly underreported, true incidence substantially exceeds all reported figures cited in this report [2].

2. Mosquito Species in the United States

2.1 Total Species Count

There are over 3,000 mosquito species worldwide [1]. Within the United States, 176 species are recognized by entomologists, as documented by the American Mosquito Control Association [1]. A small subset are medically significant vectors of human disease. The three genera of primary public health concern in the United States are:

• Aedes spp. — Primary vectors for dengue, Zika, chikungunya, and yellow fever. Key U.S. species: Ae. aegypti (yellow fever mosquito) and Ae. albopictus (Asian tiger mosquito) [12].
• Culex spp. — Primary vectors for West Nile virus and St. Louis encephalitis. Key U.S. species: Cx. pipiens, Cx. tarsalis, Cx. quinquefasciatus [12].
• Anopheles spp. — Primary vectors for malaria. Key U.S. species: An. freeborni and An. quadrimaculatus [12].

2.2 Regional Distribution of Key Vector Species

Species	Common Name	Primary U.S. Region(s)	Diseases Vectored	Source
Aedes aegypti	Yellow fever mosquito	South/Southeast; coastal Gulf states; FL, TX, CA	Dengue, Zika, Chikungunya, Yellow Fever	[12]
Aedes albopictus	Asian tiger mosquito	Southeast, Mid-Atlantic, expanding into Northeast and Midwest	Dengue, Chikungunya, Zika	[12]
Culex pipiens	Northern house mosquito	Northeast, Midwest, Pacific Northwest	West Nile Virus, St. Louis Encephalitis	[12]
Culex tarsalis	Western encephalitis mosquito	Great Plains, Western U.S.	West Nile Virus, Western Equine Encephalitis	[12]
Culex quinquefasciatus	Southern house mosquito	South, Southeast, California	West Nile Virus, St. Louis Encephalitis	[12]
Anopheles quadrimaculatus	Common malaria mosquito	East of the Mississippi River	Malaria (locally acquired transmission rare)	[12]
Anopheles freeborni	Western malaria mosquito	Pacific Coast, western states	Malaria (locally acquired transmission rare)	[12]
Culiseta melanura	Black-tailed mosquito	Atlantic/Gulf Coast swamps; freshwater hardwood swamps in New England	Eastern Equine Encephalitis (primary enzootic vector)	[12][13]

Sources: CDC [12]; American Mosquito Control Association [1]; EPA [13]. Note: This table covers medically significant species only; 176 total U.S. species are not all listed here.

3. Mosquito Population Density by U.S. Region

Mosquito population density is influenced by temperature, precipitation or rainfall, standing water availability, and vegetation cover. No federal database maintains a single, standardized national mosquito density count; density levels below represent qualitative assessments derived from published surveillance activity reports, entomological field studies, and state vector-control program data. ‘Estimated Density Level’ is a composite index and should not be interpreted as a measured population figure.

Region	Estimated Density Level	Climate Factors	Notes
Southeast (FL, GA, AL, MS, LA, SC)	Very High	Subtropical humidity, year-round warmth, frequent rainfall, abundant standing water	FL and LA consistently rank among highest-activity states in CDC WNV surveillance [3]
Gulf Coast (TX, LA)	Very High	High humidity, tropical storm-created standing water, mild winters	TX led all states with 176 WNV cases in 2024 per CDC ArboNET [3]
Mid-Atlantic (VA, MD, DE, NJ, NC)	High	Hot humid summers, moderate winters, coastal wetlands	Ae. albopictus established; EEE documented in NJ (2 cases) and NC (1 case) in 2024 [3]
Midwest (IL, IN, OH, MO, MN, WI)	Moderate to High	Warm summers with heavy rainfall, abundant agricultural water	IL reported 59 WNV cases in 2024; MN reported 35 [3][14]
Great Plains (NE, KS, OK, ND, SD)	Moderate to High	Hot summers; agricultural irrigation provides breeding habitat	NE reported 92 WNV cases in 2024 — 4th highest nationally [3]
Pacific Coast (CA, OR, WA)	Moderate	Mediterranean climate in CA; temperate in Pacific NW; irrigation-dependent breeding	CA reported 123 WNV cases in 2024 — 2nd highest nationally; local dengue confirmed [3]
Mountain West (CO, UT, AZ, NV, NM)	Moderate	Arid conditions limit density; monsoon season creates temporary surge	CO reported 76 WNV cases in 2024 — 5th highest nationally [3]
Northeast (NY, PA, CT, MA, RI, VT, NH, ME)	Moderate	Warm summers with high rainfall; historically shorter season, now lengthening	EEE elevated in 2024: 13 of 19 national cases in New England [3]; mosquito season expanding [9]
Hawaii & U.S. Territories	High to Very High	Tropical climate, year-round mosquito activity	PR declared dengue public health emergency 2024 (6,291 cases); USVI outbreak 2024; American Samoa outbreak July 2025 [7][15]
Alaska	Low to Moderate (seasonal)	Arctic to subarctic; activity confined to brief summer; tundra pools abundant in summer	No locally transmitted mosquito-borne diseases documented; nuisance biting only

Sources: CDC ArboNET 2024 [3]; EPA [13]; American Mosquito Control Association [1]. Density ratings are qualitative and not derived from a single standardized federal measurement system.

4. Mosquito Bite Rate Statistics

No federal agency — including CDC, EPA, or USDA — collects standardized per-capita mosquito bite rate data for the general U.S. population. This data point is not publicly available. The following table presents bite risk levels derived from seasonal vector surveillance activity, mosquito density reports, and entomological assessments published by the CDC and partner agencies. ‘Bite Risk Level’ is a qualitative composite index and does not represent a measured individual bite frequency.

Month	Bite Risk Level	Contributing Factors	Geographic Notes
January	Very Low	Cold temperatures suppress adult mosquito activity in nearly all states	Active only in South Florida, southern Texas, Hawaii, and U.S. territories year-round
February	Very Low	Winter dormancy persists across most regions	Gulf Coast and South Florida may see early nuisance activity in warm years
March	Low	Larval development begins in southern states as temperatures increase above 50°F	Southeast and Gulf Coast see first-season activity; northern states dormant
April	Low to Moderate	Overwintering Aedes eggs hatch; Culex species emerge in warm southern regions	Activity expands into Mid-Atlantic; Northeast and Midwest still largely dormant
May	Moderate	Temperatures above 50°F in most of the contiguous U.S.; broad breeding season begins	Northeast and Midwest season underway; Gulf Coast and Southeast moderately active
June	High	Peak breeding conditions; warm temperatures post-rainfall create standing water widely	All lower 48 states active; Gulf Coast and Southeast approaching peak
July	Very High	Peak activity month nationally; maximum temperatures and humidity; optimal mosquito development	Highest bite exposure month in most regions; WNV transmission begins escalating nationally [3]
August	Very High	Continued peak activity; highest WNV human case reporting nationally [3]	CDC ArboNET data show majority of annual WNV cases onset in July–September [2]
September	High	Activity declines gradually in northern states; South and Southeast remain active	EEE transmission peak historically; WNV cases plateau; Great Lakes and Northeast cooling
October	Moderate	Activity significantly reduced north of 40th parallel; South/Southeast still active	Gulf Coast and Florida maintain moderate activity into late October
November	Low	First hard frost kills adult populations in most regions; activity isolated to extreme South	Florida, Hawaii, and territories maintain activity
December	Very Low	Dormancy across nearly all of the country	Hawaii and Puerto Rico maintain year-round activity; South Florida sporadically active

Sources: CDC ArboNET seasonal patterns [2][3]; EPA mosquito biology [13]; Climate Central mosquito suitability analysis [9]. Risk levels are qualitative; individual exposure varies by local habitat, personal protective measures, and proximity to standing water.

Data point not publicly available: A national annual mosquito bite rate per person for the United States does not exist in any publicly accessible federal or academic dataset reviewed for this report.

5. Mosquito-Borne Disease Data (Latest Confirmed + 2026 Outlook)

5.1 Confirmed Case Data Table

Disease	Confirmed Cases	States/Territories Affected	Year & Data Status	Trend
West Nile Virus (WNV)	Long-run avg: ~2,000 cases/year, ~1,200 neuroinvasive, ~120 deaths [2] 2024: 1,791 total cases, 1,335 neuroinvasive (74.5%), 161 deaths [3] 2023: 2,628 cases, 2,022 hospitalizations, 208 deaths [2] 2025 (preliminary): >2,000 cases as of Dec 17, 2025 [4][5]	All 48 contiguous states. 2024 top 5 by case count: TX (176), CA (123), NY (98), NE (92), CO (76) [3]	2024 data: preliminary, ArboNET as of Jan 16, 2026 [3]	Increasing (2025 above-average season confirmed by AMA-CDC)
Dengue Fever	Puerto Rico 2024: 6,291 confirmed cases (191.4 per 100,000); 52.3% hospitalized; 264 severe dengue; 11 deaths (MMWR [6]) / 13 deaths (HAN-00523 [7] — later running total) USVI 2024: 208 locally acquired cases [7] Continental U.S.: Local transmission confirmed in CA, FL, TX in 2024 [15]	Territories: PR, USVI (outbreak 2024), American Samoa (outbreak Jul 2025). Continental: FL, TX, CA local transmission 2024 [15]	2024 data: MMWR Feb 20, 2025 [6]; HAN Mar 2025 [7]	Strongly Increasing (record Americas-wide year 2024: 13M cases [6])
Zika Virus	2024-2025: No sustained local transmission in continental U.S. Travel-associated cases continue sporadically. 2024-2025 ArboNET: 28 total cases, 19 travel-associated; 9 locally acquired in Puerto Rico [3-ArboNET table]	No continental U.S. local outbreak since FL/TX 2016-2017. Puerto Rico: periodic ongoing risk. Travel-associated: all 50 states	2024-2025 ArboNET provisional [3]	Stable (no continental outbreak; Puerto Rico endemic risk ongoing)
Eastern Equine Encephalitis (EEE)	2024: 19 human cases, all neuroinvasive [3]. 13 of 19 in New England (MA 4, NH 5, VT 2, RI 1, ME 1). Also: NY (2), NJ (2), WI (1), NC (1). 2025: 19 cases, 5 deaths across 9 states per ArboNET Jan 14, 2026 [3]. National annual average: 11 cases [8]	2024: 9 states — MA, NH, NY, NJ, VT, RI, WI, ME, NC [3] 2025: 9 states (same states + varies) [3]	2024 preliminary; 2025 provisional ArboNET [3]. CDC notes average 11 cases/year [8]	Above average in 2024 (cyclical pattern; 2019 record: 38 cases)
Malaria	2023: First locally acquired cases since 2003 — 8 cases in FL, 1 in TX, 1 in MD, 1 in AR [12]. 2024: Locally acquired cases still under surveillance; enhanced monitoring ongoing. Travel-associated cases reported annually from all states with international travel.	Locally acquired 2023: FL, TX, MD, AR. Travel-associated: all 50 states. Anopheles vectors present broadly east of Mississippi [12]	2023 (most recent year with confirmed local cases) [12]	Stable to Watch (locally acquired remains exceptional; 2023 reappearance warrants continued surveillance)

5.2 2025 Disease Activity Notes

West Nile Virus 2025: AMA infectious-diseases director Dr. Erica Kaufman West confirmed at an AMA-CDC joint webinar (December 5, 2025) that 2025 saw ‘41% more severe-disease cases and 32% more deaths than what is typically seen with West Nile disease’ [4]. As of December 17, 2025, over 2,000 individuals were reported infected [5]. Colorado led the 2025 season with 284 cases as of that date [5].

Dengue 2025: Puerto Rico’s public health emergency, declared March 2024, was extended through December 2025 by the Puerto Rico Department of Health [15]. As of March 7, 2025, 936 cases had been reported — a 113% increase compared to the same period in 2024 [7]. American Samoa declared a dengue outbreak on July 7, 2025 [15].

5.3 Projected 2026 Outlook

Projected 2026 Estimate: Based on confirmed 2025 elevated WNV activity and sustained dengue pressure in U.S. territories, public health agencies are expected to maintain heightened vector-borne disease surveillance.

Published vector ecology research from the University at Albany (September 2024) attributes dengue risk expansion in California, Arizona, and the Carolinas to range extension of Ae. aegypti and Ae. albopictus [16]. EEE follows a documented cyclical pattern; 2026 risk in New England is uncertain but warrants continued monitoring. No confirmed 2026 outbreak data exist as of this report’s publication date.

6. Top 10 States With Highest Mosquito-Borne Illness Reports

Rank	State	2024 WNV Cases [3]	Additional Disease Burden	Key Contributing Factors
1	Texas	176 (leads all states)	Local dengue transmission confirmed 2024 [15]	Large population, warm climate, urban Culex habitat, international travel gateway
2	California	123	Local dengue 2024; first locally acquired case confirmed [15]	Large population, Culex tarsalis range, irrigated agriculture, expanding Aedes
3	New York	98	EEE 2 cases (2024) [3]	Urban Culex pipiens density; first EEE case in NY since 2015; international travel
4	Nebraska	92	—	Culex tarsalis in agricultural plains, migratory bird flyways; high per-capita WNV burden
5	Colorado	76	—	Irrigated agriculture supports Culex tarsalis; warm Front Range summers
6	Pennsylvania	61	—	Dense population, suburban/rural mix, Culex pipiens established
7 (tie)	Illinois	59	—	Urban and agricultural Culex habitat; large population center in Chicago metro
7 (tie)	Mississippi	59	—	Subtropical climate, year-round Culex activity, rural population distribution
9 (tie)	Georgia	53	—	Expanding Aedes albopictus range; warm humid climate; urban Culex
9 (tie)	Louisiana	53	—	Subtropical wetlands, Year-round Culex activity, tropical storm flooding

Note: Massachusetts (#8 in EEE burden with 4 cases in 2024) and New Hampshire (#1 in EEE with 5 cases in 2024) would rank prominently if EEE burden alone were used; their WNV totals (19 and 1 respectively) are lower. Puerto Rico, not ranked here as a state, reported 6,291 dengue cases in 2024 — far exceeding any continental state [6].

Source: CDC ArboNET 2024 provisional data, current as of January 16, 2026 [3].

7. State-by-State Mosquito Season Guide (All 50 States)

Season timings are based on average annual climate patterns, published state vector-control program reports, and CDC entomological guidance. Actual conditions vary by year, elevation, and local microclimate. ‘Season Start’ refers to consistent adult mosquito activity; ‘Season End’ refers to final hard freeze or sustained temperatures below 50°F. Risk Level reflects both nuisance bite pressure and vector-borne disease history combined.

Precise statewide mosquito season boundaries by start/end date are not published as a unified federal dataset; dates represent regional averages derived from CDC seasonal surveillance patterns and state health department reports.

NOTE: The above visual is for illustrative purposes only and does not represent precise data trends; please refer to the detailed table below for confirmed figures.

State	Season Start (Avg.)	Peak Months	Season End (Avg.)	Risk Level	Notes
Alabama	March	June–August	November	High	Subtropical; high Aedes and Culex activity
Alaska	June	July	August	Low	Nuisance biting only; no documented local MBD transmission
Arizona	March	June–September	November	Moderate	2024 WNV: 31 cases; local dengue confirmed 2024 [3][15]
Arkansas	March	June–August	October	High	Culex quinquefasciatus dominant; WNV burden moderate
California	March–April	June–September	October–November	High	2024 WNV: 123 cases; local dengue 2024 [3][15]
Colorado	April–May	July–August	September	Moderate–High	2024 WNV: 76 cases; 5th highest nationally [3]
Connecticut	May	July–August	October	Moderate–High	EEE risk; expanding Ae. albopictus
Delaware	April–May	July–August	October	Moderate	2024 WNV: 2 cases [3]
Florida	January (S. FL)	May–October	Year-round in S. FL	Very High	Local dengue transmission 2024 and 2025 [15]; year-round Aedes activity
Georgia	March	June–September	November	High	2024 WNV: 53 cases [3]; Ae. albopictus well established
Hawaii	Year-round	Year-round	Year-round	High	Ae. aegypti and Ae. albopictus present; dengue risk for residents and travelers
Idaho	May	July–August	September	Low–Moderate	2024 WNV: 6 cases [3]
Illinois	April–May	July–August	October	Moderate–High	2024 WNV: 59 cases [3]; urban Culex pipiens dominant
Indiana	April–May	July–August	October	Moderate	2024 WNV: 11 cases [3]
Iowa	April–May	July–August	October	Moderate	2024 WNV: 21 cases [3]
Kansas	April	June–September	October	Moderate–High	2024 WNV: 23 cases [3]
Kentucky	April	June–August	October	Moderate	2024 WNV: 9 cases [3]
Louisiana	February–March	May–October	December	Very High	2024 WNV: 53 cases [3]; extensive coastal wetlands
Maine	May–June	July–August	September	Moderate	EEE 1 case in 2024 [3]; Culiseta melanura in swamps
Maryland	April–May	July–August	October	Moderate	2024 WNV: 23 cases [3]
Massachusetts	May	July–September	October	High	2024 EEE: 4 cases [3]; first EEE death 2024 [3]
Michigan	May	June–August	September–October	Moderate	2024 WNV: 31 cases [3]
Minnesota	May	June–August	September	Moderate–High	2024 WNV: 35 cases per MN DOH [14]
Mississippi	March	June–September	November	Very High	2024 WNV: 59 cases [3]; subtropical climate
Missouri	April	June–August	October	Moderate–High	2024 WNV: 13 cases [3]
Montana	May–June	July–August	September	Low–Moderate	2024 WNV: 4 cases [3]
Nebraska	April–May	June–September	October	High	2024 WNV: 92 cases [3]; 4th highest nationally
Nevada	March–April	June–September	October	Moderate	2024 WNV: 27 cases [3]
New Hampshire	May–June	July–August	October	Moderate–High	2024 EEE: 5 cases, 2 deaths [3]; highest EEE burden in 2024
New Jersey	April–May	July–August	October	Moderate–High	2024 WNV: 39 cases; EEE 2 cases [3]
New Mexico	April–May	July–September	October	Moderate	2024 WNV: 28 cases [3]
New York	May	July–August	October	Moderate–High	2024 WNV: 98 cases; EEE 2 cases (first human case since 2015) [3]
North Carolina	March–April	June–September	November	High	2024 WNV: 26 cases; EEE 1 case [3]
North Dakota	May–June	July–August	September	Moderate	2024 WNV: 38 cases [3]
Ohio	April–May	July–August	October	Moderate–High	2024 WNV: 14 cases [3]
Oklahoma	March–April	June–September	November	High	2024 WNV: 39 cases [3]
Oregon	May	June–August	October	Low–Moderate	Low WNV burden; 2024 WNV: 0 cases in ArboNET table [3]
Pennsylvania	April–May	July–August	October	High	2024 WNV: 61 cases [3]; 6th highest nationally
Rhode Island	May	July–August	October	Moderate	2024 EEE: 1 case [3]; WNV: 6 cases
South Carolina	March	June–September	November	High	2024 WNV: 18 cases [3]; subtropical wetlands
South Dakota	May	July–August	September	Moderate	2024 WNV: 21 cases [3]
Tennessee	March–April	June–August	November	High	2024 WNV: 9 cases [3]; Ae. albopictus expanding
Texas	February (S. TX)	May–October	December (S. TX)	Very High	2024 WNV: 176 cases — leads all states [3]; local dengue 2024 [15]
Utah	April–May	July–August	September–October	Moderate	2024 WNV: 14 cases; all neuroinvasive [3]
Vermont	May–June	July–August	October	Moderate	2024 EEE: 2 cases, 1 death [3]
Virginia	April	June–August	October	Moderate–High	2024 WNV: 10 cases [3]
Washington	May	June–August	October	Low–Moderate	2024 WNV: 1 case [3]
West Virginia	April–May	July–August	October	Low–Moderate	2024 WNV: 2 cases [3]
Wisconsin	May	June–August	September	Moderate	2024 WNV: 34 cases; EEE 1 case [3]
Wyoming	May–June	July–August	September	Low–Moderate	2024 WNV: 2 cases [3]

Sources: CDC ArboNET 2024 provisional data (as of Jan 16, 2026) [3]; CDC seasonal surveillance patterns [2]; MN Dept. of Health [14]; Climate Central [9]. WNV case counts are from ArboNET 2024 provisional table.

8. Climate Change & Mosquito Trends

Warming temperatures and shifting precipitation patterns are altering when and where mosquitoes can survive and breed in the United States. Climate Central’s peer-reviewed analysis (published Washington Post, August 22, 2024) found that more than two-thirds of the contiguous U.S. experienced an increase in ‘mosquito days’ — defined as days with average relative humidity at or above 42% and temperatures between 50°F and 95°F — over the past four decades [9].

Published climate modeling projects that warming autumns and earlier springs could extend the U.S. mosquito season by up to two months by 2050 [11]. These trends have direct implications for US mosquito statistics 2026 and forward projections.

8.1 Trend Comparison Table

Period	U.S. Avg. Temp Change (vs. pre-industrial baseline)	Observed Mosquito Season Change	Documented Disease / Vector Impact
1980–2009 (reference baseline)	Approx. +0.8°C vs. pre-industrial (IPCC AR6 [17])	Reference baseline for mosquito-day analysis [9]	WNV introduced to U.S. 1999; malaria absent locally since 1970s; Ae. albopictus range expanding
2010–2015	Approx. +1.0°C vs. pre-industrial (IPCC AR6 [17])	Modest early-season expansion in mid-latitudes documented in surveillance data [9]	Ae. albopictus continues northward range expansion; sporadic dengue local cases in FL and TX
2016–2020	Approx. +1.1–1.2°C vs. pre-industrial (IPCC AR6 [17])	Northeast cities show 10–17 more mosquito days than 1980-2009 baseline in some locations [9]	EEE outbreak 2019 (38 cases, highest on record per CDC [8]). First locally acquired dengue in CA confirmed.
2021–2024	Approx. +1.2–1.3°C vs. pre-industrial (estimated per IPCC AR6 trajectory [17])	Vermont and other Northeast states gaining 15–17 additional mosquito-suitable days vs. baseline [9]	Local dengue transmission confirmed in CA, AZ, NC, and FL 2024 [15]. EEE above average in 2024 New England (13 of 19 cases) [3]. WNV 2025 above-average season [4].
Projected 2026 Estimate	Continued warming expected under all IPCC scenarios	Further season lengthening in Northeast and Pacific Northwest; possible heat-induced summer compression in extreme desert Southwest	Projected: Expanded Ae. aegypti and Ae. albopictus ranges; rising locally acquired dengue risk; EEE cycle watch [16]
Projected 2050 (long-term)	+1.5°C minimum under low-emission IPCC scenarios; up to +3°C under high-emission scenarios [17]	Published modeling projects U.S. mosquito season potentially 1–2 months longer [11]	Harvard Gazette (Oct 2024) reports substantially increased geographic range for dengue and WNV under continued warming. Malaria local transmission theoretically possible in more areas but public health infrastructure remains a strong barrier [11].

8.2 Mechanisms of Climate-Mosquito Interaction

Published vector ecology research from the University at Albany (September 2024) identifies the key mechanisms through which climate change is influencing U.S. mosquito populations and disease risk:

(1) expanded geographic range of Ae. aegypti and Ae. albopictus into higher latitudes as temperatures become thermally suitable, driving the first locally acquired dengue cases in CA, AZ, NC, and FL in recent years [16];

(2) accelerated mosquito life cycles leading to shorter mosquito lifespan due to higher ambient temperatures, shortening intervals between blood meals and egg-laying;

(3) longer transmission seasons resulting from milder winters and earlier springs [9]; and

(4) increased availability of larval habitat following intensified precipitation events [17].

9. Urban vs. Rural Mosquito Trends

Mosquito ecology and disease risk differ substantially between urban and rural environments. No single federal database maintains standardized national urban/rural mosquito density comparisons; the patterns below are documented in CDC vector surveillance literature and peer-reviewed entomological research. Figures in this section are qualitative unless otherwise cited.

Factor	Urban Settings	Rural Settings	Public Health Implication
Dominant Species	Culex pipiens; Aedes albopictus (container-breeding); peridomestic species adapted to urban water sources	Culex tarsalis (agricultural/plains); Aedes vexans (floodwater); Anopheles spp. (freshwater wetlands)	Urban environments favor Aedes-vectored disease risk (dengue, Zika); rural settings favor WNV and EEE vector exposure
Primary Breeding Sites	Containers (birdbaths, clogged gutters, catch basins, tires, storm drains, flower pots)	Natural wetlands, rice fields, irrigation ditches, floodplain pools, livestock troughs, marshes	Urban breeding is highly controllable through source-reduction campaigns; rural breeding often requires organized abatement programs
WNV Exposure	High: Culex pipiens bites humans in dense urban environments; 2024 top WNV states include CA (123) and NY (98) — major urban centers [3]	High: Culex tarsalis is a highly efficient WNV vector in agricultural plains; NE (92 cases, 2024) demonstrates rural burden [3]	WNV burden is documented in both urban and rural states; no clear geographic preference by case count
EEE Risk	Low: Culiseta melanura prefers freshwater hardwood swamps, largely absent from urbanized areas	High in specific habitats: wooded swamp margins and rural residential areas near endemic swamps in MA, NH, NY, NJ, VT, ME, WI [3]	EEE is primarily a rural/suburban risk; 2024 cases concentrated near freshwater hardwood swamp habitats [3][13]
Dengue Risk	Higher: Ae. aegypti is strongly peridomestic, thriving in dense housing with container water; local dengue 2024 in urban FL, TX, CA [15]	Lower overall, except near Ae. albopictus habitat adjacent to human dwellings	Local dengue transmission risk concentrated in urban/suburban environments with established Ae. aegypti populations
Vector Control Access	Greater access to municipal abatement programs, professional pest control services, public education campaigns	Less consistent access to organized vector control; higher reliance on personal protective measures	Resource disparities can elevate per-capita disease risk in rural communities; EPA and AMCA recommend IVM programs at county level [1][13]
Urban Heat Island Effect	Elevated local temperatures can extend mosquito activity 2–4 weeks beyond regional seasonal average [9]	Temperature generally tracks regional climate averages without amplification	Urban heat islands identified by Climate Central analysis as a factor extending WNV and Aedes activity in major metro areas [9]

Sources: CDC [2][3][12]; EPA [13]; University at Albany vector ecology research [16]; Climate Central [9]. Urban/rural density comparisons are qualitative due to absence of a unified national urban-rural mosquito density database.

10. Economic Impact of Mosquito Control in the U.S.

Economic Category	Estimated Value / Metric	Data Year	Source
Total U.S. mosquito control market	$1,873.4 million (~$1.87 billion)	2024	Precision Business Insights [10]
Projected U.S. mosquito control market (2031)	$2,911.2 million (~$2.91 billion) at CAGR of 6.5%	Projected	Precision Business Insights [10]
U.S. mosquito repellent market	$1,533.3 million (~$1.53 billion)	2024	IMARC Group [18]
U.S. mosquito repellent market projected (2033)	$3,039.7 million at CAGR of 7.9%	Projected	IMARC Group [18]
North America insect repellent market	$1.6 billion	2023	Grand View Research [19]
Total U.S. structural pest control revenue (all pests)	$12.654 billion (up 7.9% from 2023)	2024	Specialty Consultants LLC / NPMA [20]
U.S. mosquito repellent share of insect repellent market	50.7% (by revenue)	2024	Grand View Research [19]
Pest control product expenditures (all categories)	Exceeded $1 billion for first time; up 8.9% from 2023	2024	Specialty Consultants LLC / NPMA [20]
Healthcare costs of U.S. mosquito-borne diseases	Data not publicly available in consolidated form	—	No single federal source provides this figure

The economic footprint of mosquito activity extends beyond direct control spending to include lost outdoor workforce productivity, tourism impacts in peak-activity seasons, and the costs of diagnosing and treating mosquito-borne illness. A consolidated U.S.-specific disease healthcare cost estimate was not identified in publicly available federal data sources as of this report’s compilation date.

Commercial market estimates cited above carry methodological variance; figures from different research firms for the same market category may differ materially, as shown by the repellent market where estimates range from $1.53B (IMARC) to $1.6B (Grand View North America). These should be interpreted as directional market size estimates, not precise official statistics.

11. Prevention & Control Methods

The following table presents mosquito prevention and control methods used in the United States, ranked by documented CDC recommendation priority, evidence of effectiveness, and adoption in public health programs. Rankings reflect CDC and EPA guidance as of the report’s publication date.

Rank	Method	Mechanism	CDC/EPA Status	Trend
1	EPA-registered insect repellents (DEET, Picaridin, IR3535, OLE/PMD, 2-Undecanone)	Chemical deterrence of biting; disrupts host-detection by mosquitoes	CDC primary personal protection recommendation [12]	Stable; growing preference for DEET-free options (Picaridin, PMD) per market data [18]
2	Elimination of standing water (source reduction)	Destroys larval breeding habitat; prevents eggs hatching to adults	Cornerstone of Integrated Vector Management (IVM); endorsed by CDC and EPA [13]	Stable; community campaigns, ordinance enforcement increasingly common
3	Larviciding (Bacillus thuringiensis israelensis [Bti], methoprene)	Biological/chemical agents kill larvae in standing water before adult emergence	EPA-registered; preferred for low environmental impact [13]	Increasing: Bti preferred for reduced non-target effects; drone applications expanding
4	Permethrin-treated clothing and gear	Contact insecticide applied to fabrics; kills or repels mosquitoes on contact with clothing	CDC-recommended, especially for outdoor workers, military, travelers [12]	Increasing adoption; commercially pre-treated garments now widely available
5	Adulticiding (ULV truck/aerial spraying with pyrethroids or organophosphates)	Ultra-low volume insecticide mist applied to kill adult mosquitoes; deployed during outbreaks	EPA-registered; CDC-endorsed for outbreak control scenarios [13]	Stable; public preference shifting toward targeted application over broad-area spraying
6	Window and door screens; air conditioning	Physical barriers prevent mosquito entry into living spaces	Passive but highly effective; implicit in CDC vector avoidance guidance [12]	Stable; standard in most U.S. housing stock
7	Biological control (Gambusia fish, Bti, Bacillus sphaericus)	Natural predators and microbial agents reduce larval populations in water bodies	Endorsed for environmentally sensitive areas [13]	Increasing: preferred method in wetland and natural area management contexts
8	Genetically modified mosquito releases (Oxitec Friendly Aedes technology)	GM males produce offspring that die before reproducing, reducing wild Ae. aegypti populations	EPA has approved field release trials in FL and CA [13]	Emerging; limited scale; public acceptance variable; ongoing EPA-monitored trials
9	Mosquito surveillance traps (gravid traps, CO2 traps, BG-Sentinel)	Traps used for vector monitoring and disease surveillance; secondarily for control	Recommended by CDC and AMCA for surveillance programs [1][12]	Stable for surveillance; consumer control traps have limited proven population-level efficacy
10	Integrated Vector Management (IVM) programs (community-wide)	Coordinated multi-strategy approach: source reduction, larviciding, adulticiding, public education	CDC and WHO gold standard for sustained community-level mosquito control [1][13]	Growing: state and county vector control programs increasingly formalizing IVM frameworks

Note: Ultrasonic electronic mosquito repellent devices are NOT included because published evidence does not support their effectiveness; the American Mosquito Control Association explicitly states they provide no meaningful protection [1]. Sources: CDC [1][12]; EPA [13]; AMCA [1].

12. Methodology

12.1 Data Sources Used

This report draws exclusively on primary government surveillance data, peer-reviewed publications, and published market research. No secondary aggregators, forums, or unattributed online content were used as data sources. All figures that appear as confirmed data have a numbered citation traceable to a specific document.

• CDC ArboNET System: Primary source for all human mosquito-borne disease case counts. 2024 data: provisional, current as of January 16, 2026. 2025 data: provisional as of January 13-14, 2026. Both datasets are subject to revision. Direct PDF source for state-level 2024 ArboNET table obtained from California West Nile Virus Website, distributing CDC ArboNET document [3].
• CDC Morbidity and Mortality Weekly Report (MMWR): Padda H, Jacobs D, Gould CV, et al. ‘West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2023.’ MMWR 2025;74:358-364. Used for long-run average case counts and the 2023 season summary [2].
• CDC MMWR: Ware-Gilmore F, et al. ‘Dengue Outbreak and Response — Puerto Rico, 2024.’ MMWR 2025;74:54-60. Used for confirmed Puerto Rico dengue 2024 case counts, hospitalizations, and deaths [6].
• CDC Health Alert Network (HAN-00523): ‘Ongoing Risk of Dengue Virus Infections and Updated Testing Recommendations in the United States.’ March 2025. Used for 2025 dengue activity updates and the operational death toll figure of 13 [7].
• American Medical Association (AMA): AMA-CDC joint webinar summary, December 5, 2025, with Dr. Erica Kaufman West, AMA infectious-diseases director. Used for 2025 WNV severity metrics (41% more severe cases; 32% more deaths) [4].
• Vax-Before-Travel: Report citing CDC data showing over 2,000 WNV cases as of December 17, 2025, with Colorado at 284 cases [5].
• CDC Current Dengue Outbreak page: Used for 2025 Puerto Rico outbreak extension, USVI ongoing outbreak, and American Samoa July 2025 outbreak declaration [15].
• Utah DHHS 2024 Mosquito-Borne Disease Annual Report: Provided 2024 WNV national case count (1,791) derived from CDC ArboNET, and comparative state-level data [3-Utah].
• Minnesota Department of Health: 2024 WNV Minnesota statistics confirming 35 cases [14].
• EPA: General Information about Mosquitoes (Updated July 10, 2025); EEE Surveillance and Control Guidelines. Used for vector control method endorsements and species biology [13].
• American Mosquito Control Association (AMCA): Species count (176), general biology, control method information [1].
• IPCC Sixth Assessment Report (AR6): Temperature change baselines for climate comparison table [17].
• Climate Central analysis (Stevens, Washington Post, August 22, 2024): Mosquito day increase data by region and city [9].
• Harvard Gazette (October 16, 2024): Climate-mosquito disease projection to 2050 [11].
• University at Albany vector ecology research (September 23, 2024): Range expansion mechanisms for Ae. aegypti and Ae. albopictus [16].
• Market Research: Precision Business Insights (USA mosquito control market) [10]; IMARC Group (U.S. mosquito repellent market) [18]; Grand View Research (North America insect repellent) [19]; Specialty Consultants LLC / NPMA (total pest control revenue) [20].
• NCBI StatPearls (December 2025): EEE case fatality rate ranges [21].

12.2 Compilation Method

Data were compiled through systematic review of publicly available federal surveillance databases, peer-reviewed publications (accessed via PubMed/PMC and MMWR), and government health authority documents.

All cited figures were cross-referenced against primary source documentation. Where multiple sources reported the same metric with variation, the most recent official federal source (CDC MMWR or ArboNET) was prioritized as the authoritative value. Secondary commercial market estimates were used only for economic data unavailable from federal sources, and are identified as such.

12.3 Limitations

• Under-reporting: All mosquito-borne disease case counts substantially underestimate true incidence. Approximately 80% of WNV infections are asymptomatic. Only about 1 in 150 WNV infections results in neuroinvasive disease [2]. Non-neuroinvasive illness is significantly underreported.
• Reporting lag: 2024 ArboNET data (as of January 16, 2026) are still labeled preliminary and subject to change. Final 2025 annual totals are not yet available.
• No standardized national bite rate: Per-capita mosquito bite rates are not collected by any federal agency. Bite risk levels in Section 4 are qualitative composites, not measured data.
• Market data variance: Commercial market research estimates vary by firm methodology; the U.S. mosquito repellent market is estimated variously at $1.09B–$1.53B depending on geographic scope and product definition. All figures are noted with their source and should be interpreted as directional estimates.
• State season timings: Represent regional averages; local variation by elevation, microclimate, and land use can shift actual timing by several weeks. No single federal dataset publishes state-by-state mosquito season start/end dates.
• Density ratings: Population density levels in Section 3 are qualitative assessments not derived from a standardized federal measurement system.

12.4 Projection Explanation

All entries labeled ‘Projected 2026 Estimate’ are forward-looking assessments based on:

1. confirmed trajectory of observed data through early 2026;
2. published climate modeling for mosquito range expansion (University at Albany [16]; Harvard Gazette [11]);
3. established epidemiological cyclical patterns (EEE 5-8 year cycle, per CDC historical data [8]); and
4. market growth modeling from industry research firms.

Projections do not represent confirmed outcomes and should be interpreted as directional estimates carrying substantial uncertainty. They are clearly distinguished from confirmed data throughout this report.

Frequently Asked Questions (FAQs)

References

[1] American Mosquito Control Association (AMCA). Mosquito Information: Species and Biology. Available at: https://www.mosquito.org/mosquito-information/. Accessed February 2026.

[2] Padda H, Jacobs D, Gould CV, et al. West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2023. MMWR Morb Mortal Wkly Rep 2025;74:358–364. DOI: http://dx.doi.org/10.15585/mmwr.mm7421a1. Available at: https://www.cdc.gov/mmwr/volumes/74/wr/mm7421a1.htm. Published June 12, 2025.

[3] CDC ArboNET. West Nile Virus and other nationally notifiable arboviruses — United States, 2024. Provisional data as of January 14-16, 2026. State-level tabular data distributed by California West Nile Virus Website: https://westnile.ca.gov/download?download_id=5083. Also available: CDC Historic Data (1999-2024) dashboard: https://www.cdc.gov/west-nile-virus/data-maps/historic-data.html.

[4] American Medical Association (AMA). West Nile Virus Deaths Up by 32% in 2025. December 5, 2025. Available at: https://www.ama-assn.org/public-health/infectious-diseases/west-nile-virus-deaths-32-2025. Quoting: Dr. Erica Kaufman West, AMA Infectious Diseases Director, AMA-CDC Joint Webinar.

[5] Vax-Before-Travel. West Nile Virus Causes Deaths Throughout Europe and the USA. December 17, 2025. Available at: https://www.vax-before-travel.com/2025/12/17/west-nile-virus-causes-deaths-throughout-europe-and-usa. (Citing CDC data as of December 17, 2025.)

[6] Ware-Gilmore F, Rodriguez DM, Ryff K, et al. Dengue Outbreak and Response — Puerto Rico, 2024. MMWR Morb Mortal Wkly Rep 2025;74:54–60. DOI: 10.15585/mmwr.mm7405a1. Published February 20, 2025. Available at: https://www.cdc.gov/mmwr/volumes/74/wr/mm7405a1.htm.

[7] Centers for Disease Control and Prevention (CDC). Health Alert Network (HAN-00523): Ongoing Risk of Dengue Virus Infections and Updated Testing Recommendations in the United States. March 2025. Available at: https://www.cdc.gov/han/php/notices/han00523.html.

[8] Centers for Disease Control and Prevention (CDC). Data and Maps for Eastern Equine Encephalitis. Available at: https://www.cdc.gov/eastern-equine-encephalitis/data-maps/index.html. Accessed February 2026. (‘On average, 11 cases of eastern equine encephalitis virus disease are reported annually in the U.S.’)

[9] Stevens H. Mosquito Season Is Changing. See If It Has Gotten Longer in Your Area. Washington Post (Climate Central analysis). August 22, 2024. Available at: https://www.washingtonpost.com/climate-environment/interactive/2024/mosquito-season-state-change-global-warming/.

[10] Precision Business Insights. USA Mosquito Control Market Outlook, Size, Share Analysis 2030. Market value: $1,873.4M (2024); projected $2,911.2M (2031); CAGR 6.5%. Available at: https://www.precisionbusinessinsights.com/market-reports/usa-mosquito-control-market. Accessed February 2026.

[11] Harvard Gazette. Threat of Mosquito-Borne Diseases Rises with Global Temperature. October 16, 2024. Available at: https://news.harvard.edu/gazette/story/2024/10/threat-of-mosquito-borne-diseases-rises-with-global-temperature/. (Reporting on published peer-reviewed climate-disease modeling research.)

[12] Centers for Disease Control and Prevention (CDC). About Mosquitoes in the United States. Updated June 4, 2024. Available at: https://www.cdc.gov/mosquitoes/about/about-mosquitoes-in-the-united-states.html.

[13] U.S. Environmental Protection Agency (EPA). General Information about Mosquitoes. Updated July 10, 2025. Available at: https://www.epa.gov/mosquitocontrol/general-information-about-mosquitoes. Also: EPA EEE Surveillance and Control Guidelines, September 2024.

[14] Minnesota Department of Health. West Nile Virus Maps and Statistics. 2024 data (‘In 2024, 35 WNV disease cases were reported in Minnesota’). Available at: https://www.health.state.mn.us/diseases/westnile/statistics.html. Accessed February 2026.

[15] Centers for Disease Control and Prevention (CDC). Current Dengue Outbreak Information. Updated 2025. Available at: https://www.cdc.gov/dengue/outbreaks/2024/index.html. (Cites PR outbreak extension through Dec 2025; USVI; American Samoa outbreak July 7, 2025; local transmission in FL, TX, CA 2024; FL 2025.)

[16] University at Albany. Q&A: The Intersection of Mosquito-Borne Disease and Climate Change. September 23, 2024. Available at: https://www.albany.edu/news-center/news/2024-qa-intersection-mosquito-borne-disease-and-climate-change.

[17] Intergovernmental Panel on Climate Change (IPCC). Sixth Assessment Report (AR6), Working Group I: The Physical Science Basis. 2021. Available at: https://www.ipcc.ch/report/ar6/wg1/. (Temperature change baselines referenced in Section 8.)

[18] IMARC Group. United States Mosquito Repellent Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033. Market value: $1,533.3M (2024); projected $3,039.7M (2033); CAGR 7.9%. Available at: https://www.imarcgroup.com/united-states-mosquito-repellent-market. Accessed February 2026.

[19] Grand View Research. North America Mosquito Repellent Market Size & Share Analysis 2024-2030. Market value: $1.6B (North America, 2023); U.S. insect repellent market: $376.9M (2024). Available at: https://www.grandviewresearch.com/industry-analysis/north-america-mosquito-repellent-market. Accessed February 2026.

[20] National Pest Management Association (NPMA) / Specialty Consultants LLC. U.S. Pest Control Industry Shows Remarkable Resilience with Nearly 8% Growth in 2024. Total structural pest control revenue: $12.654 billion (2024). Available at: https://www.npmapestworld.org/. Accessed February 2026.

[21] Wormsbecker A, Weatherhead JE. Eastern Equine Encephalitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Updated December 14, 2025. Available at: https://www.ncbi.nlm.nih.gov/sites/books/NBK557692/. (EEE case fatality rate: approximately 30-40%, with reports as high as 41%.)